OSCR
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a revenue discount but a book premium; lacks traditional value anchors.
- Very low P/S ratio (0.48)
- High Price/Book (5.61)
- No Graham Number due to lack of earnings
Growth is present in sales but not translating to the bottom line.
- Consistent 17% revenue growth
- EPS growth is crashing (-100% YoY)
- Failure to meet analyst expectations
Historical performance is characterized by volatility and losses.
- Recent 1-year price recovery
- Long history of negative earnings
- Poor surprise track record
Deterministic health scores indicate a weak financial foundation.
- Debt/Equity is relatively low
- Piotroski F-Score 2/9
- Current Ratio < 1.0
Non-dividend paying growth stock.
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OSCR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OSCR
Oscar Health, Inc.
Primary
|
-18.9% | +168.3% | +41.9% | +2.0% | +60.9% | +12.4% |
|
ALKS
Alkermes plc
Peer
|
+53.2% | +17.7% | +17.2% | +7.2% | +11.8% | -0.1% |
|
CHE
Chemed Corporation
Peer
|
-8.1% | -24.7% | -22.6% | -3.3% | +12.6% | +9.5% |
|
CAI
Caris Life Sciences, Inc.
Peer
|
-33.0% | -33.0% | -33.0% | -40.6% | -1.3% | +4.9% |
|
MIRM
Mirum Pharmaceuticals, Inc.
Peer
|
+417.6% | +286.1% | +143.7% | +33.7% | +6.4% | +0.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OSCR
Oscar Health, Inc.
|
BEARISH | $5.56B | - | -44.4% | -3.8% | $18.46 | |
|
ALKS
Alkermes plc
|
NEUTRAL | $5.62B | 23.57 | 14.7% | 16.4% | $33.71 | Compare |
|
CHE
Chemed Corporation
|
BEARISH | $5.65B | 22.99 | 25.3% | 10.5% | $421.11 | Compare |
|
CAI
Caris Life Sciences, Inc.
|
NEUTRAL | $5.3B | - | -45.4% | -8.4% | $18.75 | Compare |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
BEARISH | $5.82B | - | -8.6% | -4.5% | $96.49 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | BERTOLINI MARK T | Chief Executive Officer | Purchase | 1,000,000 | $11,920,000 |
| 2026-04-02 | BERTOLINI MARK T | Chief Executive Officer | Stock Award | 5,733,334 | - |
| 2026-03-12 | BLACKLEY RICHARD SCOTT | Chief Financial Officer | Gift | 150,000 | - |
| 2026-03-02 | BERTOLINI MARK T | Chief Executive Officer | Stock Award | 1,596,877 | - |
| 2026-03-02 | BLACKLEY RICHARD SCOTT | Chief Financial Officer | Stock Award | 134,847 | - |
| 2026-03-02 | BLACKLEY RICHARD SCOTT | Chief Financial Officer | Sale | 19,221 | $257,369 |
| 2026-03-02 | MCANANEY ADAM | Officer | Stock Award | 67,424 | - |
| 2026-03-02 | MCANANEY ADAM | Officer | Sale | 18,710 | $250,527 |
| 2026-03-02 | SCHLOSSER MARIO T | Chief Technology Officer | Stock Award | 189,141 | - |
| 2026-03-02 | SCHLOSSER MARIO T | Chief Technology Officer | Sale | 24,335 | $325,846 |
| 2026-03-02 | LIANG JANET | Officer | Stock Award | 106,458 | - |
| 2026-03-02 | LIANG JANET | Officer | Sale | 7,453 | $99,796 |
| 2026-03-02 | BALTRUS VICTORIA | Officer | Stock Award | 17,300 | - |
| 2026-03-02 | BALTRUS VICTORIA | Officer | Sale | 4,638 | $62,103 |
| 2026-01-08 | SCHLOSSER MARIO T | Chief Technology Officer | Sale | 23,038 | $406,621 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Oscar Health submitted its 10-K filing on February 13, 2026, which includes comprehensive disclosures regarding its business operations and financial condition. The report provides detailed management analysis of results of operations and outlines the primary risk factors facing the company.
Oscar Health issued $410 million in convertible senior subordinated notes due 2030 with an annual interest rate of 2.25%. To manage the offering, the company entered into capped call transactions, though it faces risks related to potential equity dilution upon conversion and cash repurchase obligations in the event of a fundamental change.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning OSCR from our newsroom.